NuvOx Therapeutics Files for $20 Million IPO to Advance Hypoxia-Targeting NanO2 Platform
核心洞察
NuvOx Therapeutics (搜索), a Phase II biotech, filed for a $20 million IPO on NYSE American to fund its NanO2 oxygen therapeutic pipeline targeting tissue hypoxia.
Lead programs in glioblastoma and acute ischemic stroke (搜索) have completed Phase Ib/IIa trials, with Phase IIb studies now underway in both indications.
The GBM Phase IIb trial has fully enrolled 93 patients, while a UK investigator-initiated stroke trial has treated 17 patients to date.
NuvOx Therapeutics (搜索), a clinical-stage biopharmaceutical company focused on developing oxygen therapeutics for hypoxia-driven diseases, filed with the SEC on July 17, 2026, to raise up to $20 million in an initial public offering. The Tucson, Arizona-based company plans to offer approximately 2.86 million shares at a price range of $6.00 to $8.00 per share, with a proposed listing on the NYSE American under the ticker symbol "NUOX." At the midpoint of the proposed range, NuvOx would command a fully diluted market value of $98 million. ThinkEquity (搜索) is serving as the sole bookrunner on the deal.
The company's core asset is NanO2, an intravenously administered oxygen therapeutic based on dodecafluoropentane, formulated as a nanoemulsion that transitions to a gas phase at body temperature. This unique mechanism enables high oxygen-carrying capacity and rapid diffusion into hypoxic tissues. Because NanO2's particles are substantially smaller than red blood cells, they can partition into tissue and facilitate oxygen transfer from blood to areas where it is most critically needed.
Clinical Pipeline and Progress
NuvOx's lead programs target acute ischemic stroke (搜索) and glioblastoma multiforme (搜索) (GBM), both of which have completed Phase Ib/IIa trials and are currently being evaluated in Phase IIb studies. The U.S.-based Phase IIb GBM trial has completed enrollment with 93 patients and is now in follow-up. Concurrently, a UK investigator-initiated Phase IIb stroke trial is underway, with 17 patients treated to date.
Additional programs are in earlier-stage development for acute respiratory distress syndrome (搜索) (ARDS) and sickle cell anemia (搜索). A Canadian Phase Ib dose-escalation study in respiratory distress has completed two cohorts with 12 patients, demonstrating encouraging oxygenation improvements, and is expected to be followed by a Phase II ARDS trial. The company has received orphan drug designation for GBM (2015) and sickle cell disease (2016), as well as Fast Track designation for stroke.
Notably, no pharmaceutical treatments are currently approved specifically for hypoxia associated with acute ischemic stroke (搜索), GBM, or ARDS, positioning NanO2 in a market with significant unmet medical need.
Market Opportunity
The addressable markets for NuvOx's lead indications are substantial. The GBM market was valued at $2.5 billion in 2022 and is projected to reach $6.0 billion by 2032, according to Emergen Research. The U.S. stroke diagnostics and therapeutics market is expected to grow from $5.4 billion in 2023 to $11.6 billion by 2032, representing a compound annual growth rate of approximately 8.9%. Meanwhile, the U.S. ARDS market is projected to rise from $3.2 billion in 2021 to $7.1 billion by 2029, at a CAGR of approximately 10.6%.
Financial Position and Use of Proceeds
For the 12 months ended March 31, 2026, NuvOx reported revenue of $1 million, primarily from grants and services. The company posted an operating loss of $5.10 million for fiscal year 2025 and a net loss of $16.59 million. To date, NuvOx has raised $21.4 million in private financing and received $10.8 million in non-dilutive grants, with an additional $1.7 million in grants awarded but not yet received.
The IPO proceeds are earmarked for advancing the clinical pipeline: approximately $5.0 million to complete the Phase IIb GBM trial, $0.5 million for stroke trial supply, $0.5 million to complete the Phase Ib ARDS trial, $1.0 million to prepare for a Phase III GBM study, and roughly $6.0 million to fund a Phase II ARDS trial, with the remainder allocated to general development and working capital.
Intellectual Property and Manufacturing
NuvOx maintains an intellectual property estate comprising 11 issued U.S. patents and 31 foreign equivalents. The company manufactures clinical supply in-house at an ISO 7/ISO 5 cleanroom facility in Tucson, Arizona, and plans to transfer or duplicate manufacturing at a contract manufacturing organization ahead of pivotal trials. The company has also secured non-dilutive funding and collaborations with the NIH, Department of Defense, BARDA, and the UK's National Institute for Health and Care Research (NIHR).
Leadership
The company is led by Executive Chairman Evan Unger, M.D., a radiologist and serial biotech founder with over 120 issued U.S. patents who previously led teams developing multiple FDA-approved drugs. Rong Wang serves as President and CEO, bringing more than 20 years of finance and operations experience from Baxter, Ekso Bionics, and Abaxis. The board includes Richard Carmona, M.D., the 17th Surgeon General of the United States, and Marvin J. Slepian, M.D., J.D., a Regents' Professor at the University of Arizona and prolific inventor in cardiovascular devices and biomaterials.